NASDAQ · Biotechnology

Decoy Therapeutics Inc. (DCOY) Stock

$1.47 -3.29% NASDAQ: DCOY Healthcare

Valuation

MetricValue
Price$1.47
Market Cap$781993
P/E Ratio-0.06
P/B Ratio0.21
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$55.92
52-Week Low$1.46
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-315.23%
ROA-160.53%
ROCE-343.55%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio2.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-13.0M$-32.0M$-13.0M$-6.0M$-13.0M
Net Profit$-13.0M$-32.0M$-13.0M$-6.0M$-13.0M
EPS$-926.01$-1785.33$-461.04$-86.92$-25.99
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$41.0M$15.0M$7.0M$3.0M$11.0M
Total Liabilities$2.0M$4.0M$1.0M$2.0M$5.0M
Cash$29.0M$12.0M$6.0M$2.0M$11.0M
Borrowings$0$0$0$0$0

Latest News

Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors PR Newswire · Jul 15, 2026 Decoy Therapeutics Files to Register Up to 3.77 Million Shares for Resale MT Newswires · Jul 10, 2026 Top Premarket Decliners MT Newswires · Jun 30, 2026 Top Midday Gainers MT Newswires · Jun 29, 2026 DCOY Stock Nearly Doubled In Value Today – What’s Driving This Mega Rally? Stocktwits · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-10.0M$-18.0M$-13.0M$-5.0M$-5.0M
Investing Cash Flow$0$-3.0M$0$0$1.0M
Financing Cash Flow$1.0M$0$0$0$0
Net Cash Flow$18.0M$-17.0M$-6.0M$-3.0M$8.0M
Free Cash Flow$-10.0M$-19.0M$-13.0M$-5.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.51
FCF Yield-941.81%
Quick Ratio1.83
Interest Coverage0.00
Return 1Y-94.94%
Return 3Y-99.61%
Return 5Y-99.98%

Ownership

Insiders Held0.28%
Institutions Held5.76%
Institutions Float Held5.77%
Institutional HolderSharesReport Date
Tower Research Capital LLC (TRC)1,0212026-03-31
UBS Group AG5462026-03-31
Advisory Services Network, LLC412026-03-31
Morgan Stanley12026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATXIAvenue Therapeutics, Inc. $0.26 -32.94% -0.49 $856691 0.00%
ENVBEnveric Biosciences, Inc. $1.45 -4.61% -0.09 $6.49M 0.00%
GTBPGT Biopharma, Inc. $6.68 +12.08% -0.06 $8.43M 0.00%
INDPIndaptus Therapeutics, Inc. $2.51 +5.91% -0.34 $284.24M 0.00%
LIPOLipella Pharmaceuticals Inc. $0.07 +0.00% -0.05 $300354 0.00%

About Decoy Therapeutics Inc.

Decoy Therapeutics Inc. is led by CEO Frederick E. Pierce, employs 2 people, headquartered in US, publicly traded since 2015.

Decoy Therapeutics Inc. (DCOY) stock trades at $1.47 with a market capitalization of $781993. The stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of 0.21, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.46 and $55.92, and currently trades 97.4% below its 52-week high.

On profitability, Decoy Therapeutics Inc. generates a return on equity (ROE) of -315.23%, return on capital employed of -343.55%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides